These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 32208115)

  • 41. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.
    Rui X; Gu TT; Pan HF; Zhang HZ
    Int Immunopharmacol; 2019 Feb; 67():378-385. PubMed ID: 30584967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
    Wang X; Wang F; Zhong M; Yarden Y; Fu L
    Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PD-L1 immunostaining: what pathologists need to know.
    Akhtar M; Rashid S; Al-Bozom IA
    Diagn Pathol; 2021 Oct; 16(1):94. PubMed ID: 34689789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD-L1 Inhibitors for the Treatment of Prostate Cancer.
    Santoni M; Massari F; Cheng L; Cimadamore A; Scarpelli M; Montironi R; Lopez-Beltran A
    Curr Drug Targets; 2020; 21(15):1558-1565. PubMed ID: 32516098
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy.
    Hu W
    Thorac Cancer; 2020 Jan; 11(1):3-5. PubMed ID: 31722117
    [No Abstract]   [Full Text] [Related]  

  • 48. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
    J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy.
    Cao Y; Li W; Wang Z; Pang H
    Tumori; 2021 Aug; 107(4):282-291. PubMed ID: 32734832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
    Huang L; He J
    Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
    Zhang D; Huang J; Zhang C; Guan Y; Guo Q
    Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):369-379. PubMed ID: 31196371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications.
    Germanà E; Pepe L; Pizzimenti C; Ballato M; Pierconti F; Tuccari G; Ieni A; Giuffrè G; Fadda G; Fiorentino V; Martini M
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
    Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD1/PD-L1 Axis in Uro-oncology.
    Junker K; Eckstein M; Fiorentino M; Montironi R
    Curr Drug Targets; 2020; 21(13):1293-1300. PubMed ID: 32213156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
    Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
    Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
    Callea M; Pedica F; Doglioni C
    Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
    Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
    Liu H; Ye T; Yang X; Lv P; Wu X; Zhou H; Lu H; Tang K; Ye Z
    Dis Markers; 2020; 2020():8375348. PubMed ID: 32685057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.
    Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B
    Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.